Skip to main content
SpringerLink
Log in

Pathogenesis and Prevalence of Hypertension in Acromegaly

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Hypertension is an important complication of acromegaly, contributing to the increased morbidity and mortality of this condition. Prevalence of hypertension in acromegalic patients is about 35%, ranging from 18 to 60% in different clinical series, and the incidence is higher than in the general population. The lowering of blood pressure observed concomitantly with the reduction in GH levels after successful therapy for acromegaly suggests a relationship between GH and/or IGF-I excess and hypertension. The exact mechanisms underlying the development of hypertension in acromegaly are still not clear but may include several factors depending on the chronic exposure to GH and/or IGF-I excess. Experimental and clinical studies suggest that the anti-natriuretic action of GH (due to direct renal action of GH or IGF-I and/or to indirect, systemic GH or IGF-I-mediated mechanisms) may play a role in the pathogenesis of hypertension. Acromegaly is frequently associated with insulin resistance and hyperinsulinaemia which may induce hypertension by stimulating renal sodium absorption and sympathetic nervous activity. Whether sympathetic tone is altered in acromegalic hypertensive patients remains a matter of debate. Recent studies indicate that an increased sympathetic tone and/or abnormalities in the circadian activity of sympathetic system could play an important role in development and/or maintenance of elevated blood pressure in acromegaly, and may partially account for the increased risk of cardiovascular complications. Acromegalic cardiomiopathy may also concur to elevate blood pressure and can be aggravated by the coexistence of hypertension. Finally, a role of GH and IGF-I as vascular growth factors cannot be excluded. In conclusion, acromegaly is associated with hypertension, but there is still no real consensus in the literature on the mechanisms behind the development of the high blood pressure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

REFERENCES

  1. Ben-Shlomo A, Melmed S. Acromegaly. Endocrinol Metab Clin North Am 2001;30:565–583.

    Google Scholar 

  2. Nabarro JDN. Acromegaly. Clin Endocrinol 1987;26:481–512.

    Google Scholar 

  3. Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. Q J Med 1970;39:1–16.

    Google Scholar 

  4. Rajasoorya C, Holdaway IM, Wrightson P, Scott DG, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol 1994;41:95–102.

    Google Scholar 

  5. Freda PU, Wardlaw SL, Post KD. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 1998;89:353–358.

    Google Scholar 

  6. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999;2:29–41.

    Google Scholar 

  7. Melmed S. Acromegaly and cancer: Not a problem? J Clin Endocrinol Metab 2001;86:2929–2934.

    Google Scholar 

  8. Saccà L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev 1994;15:555–573.

    Google Scholar 

  9. Colao A, Marzullo P, Di Somma C, Lombardi G. Growth hormone and the heart. Clin Endocrinol (Oxf) 2001;54:137–154.

    Google Scholar 

  10. Volterrani M, Manelli F, Cicoira M, Lorusso R, Giustina A. Role of growth hormone in chronic heart failure. Therapeutic implications. Drugs 2000;60:711–719.

    Google Scholar 

  11. Gordon DA, Hill FM, Ezrin C. Acromegaly: A review of 100 cases. Can Med Assoc J 1962;87:1106–1109.

    Google Scholar 

  12. McGuffin WL Jr, Sherman BM, Roth J, Gorden P, Kahn R, Roberts WC, Frommer PL. Acromegaly and cardiovascular disorders. A prospective study. Ann Int Med 1974;81: 11–18.

    Google Scholar 

  13. Wass JA, Thorner MO, Morris DV, Rees LH, Mason AS, Jones AE, Besser GM. Long-term treatment of acromegaly with bromocriptine. Br Med J 1977;1:875–878.

    Google Scholar 

  14. Jadresic A, Banks LM, Child DF, Diamant L, Doyle FH, Fraser TR, Joplin GF. The acromegaly syndrome. Relation between clinical features, growth hormone values and radiological characteristics of the pituitary tumours.Q J Med 1982;51:189–204.

    Google Scholar 

  15. Rodrigues EA, Caruana MP, Lahiri A, Nabarro JD, Jacobs HS, Raftery EB. Subclinical cardiac dysfunction in acromegaly: Evidence for a specific disease of heart muscle. Br Heart J 1989;62:185–194.

    Google Scholar 

  16. Kraatz C, Benker G, Weber F, Ludecke D, Hirche H, Reinwein D. Acromegaly and hypertension: Prevalence and relationship to the renin-angiotensin-aldosterone system. Klin Wochenschr 1990;68:583–587.

    Google Scholar 

  17. Molitch ME. Clinical manifestations of acromegaly. Endocrinol Metab Clin North Am 1992;21:597–614.

    Google Scholar 

  18. Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V, Harris AG. Acromeglay. Clinical and biochemical features in 500 patients. Medicine (Baltimore) 1994;73:233–240.

    Google Scholar 

  19. Ohtsuka H, Komiya I, Aizawa T, Yamada T. Hypertension in acromegaly: Hereditary hypertensive factor produces hypertension by enhancing IGF-I production. Endocr J 1995;42:781–787.

    Google Scholar 

  20. Lopez-Velasco R, Escobar-Morreale HF, Vega B, Villa E, Sancho JM, Moya-Mur JL, Garcia-Robles R. Cardiac involvement in acromegaly: Specific myocardiopathy or consequence of systemic hypertension? J Clin Endocrinol Metab 1997;82:1047–1053.

    Google Scholar 

  21. Minniti G, Moroni C, Jaffrain-Rea ML, Bondanini F, Gulino A, Cassone R, Tamburrano G. Prevalence of hypertension in acromegalic patients: Clinical measurement versus 24-hour ambulatory blood pressure monitoring. Clin Endocrinol (Oxf) 1998;48:149–152.

    Google Scholar 

  22. Colao A, Baldelli R, Marzullo P, Ferretti E, Ferone D, Gargiulo P, Petretta M, Tamburrano G, Lombardi G, Liuzzi A. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 2000;85:193–199.

    Google Scholar 

  23. Weiss V, Sonka K, Pretl M, Dostalova S, Klozar J, Rambousek P, Marek J, Haas T. Prevalence of the sleep apnea syndrome in acromegaly population. J Endocrinol Invest 2000;23:515–519.

    Google Scholar 

  24. Pietrobelli DJ, Akopian M, Olivieri AO, Renauld A, Garrido D, Artese R, Feldstein CA. Altered circadian blood pressure profile in patients with active acromegaly. Relationship with left ventricular mass and hormonal values. J Hum Hypertens 2001;15:601–605.

    Google Scholar 

  25. Jaffrain-Rea ML, Moroni C, Baldelli R, Battista C, Maffei P, Terzolo M, Correra M, Ghiggi MR, Ferretti E, Angeli A, Sicolo N, Trischitta V, Liuzzi A, Cassone R, Tamburrano G. Relationship between blood pressure and glucose tolerance in acromegaly. Clin Endocrinol (Oxf) 2001;54:189–195.

    Google Scholar 

  26. Otsuki M, Kasayama S, Yamamoto H, Saito H, Sumitani S, Kouhara H, Saitoh Y, Ohnishi T, Arita N. Characterization of premature atherosclerosis of carotid arteries in acromegalic patients. Clin Endocrinol (Oxf) 2001;54:791–796.

    Google Scholar 

  27. Pickering TG. The role of ambulatory monitoring in reducing the errors associated with blood pressure measurement. Herz 1989;14:214–220.

    Google Scholar 

  28. Kaplan NM. Primary hypertension: Pathogenesis. In: Kaplan NM ed. Clinical Hypertension, 7th edn. Baltimore: Williams Wilkins, 1998:42–65.

    Google Scholar 

  29. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995;25:305–313.

    Google Scholar 

  30. Thompson D, Edelsberg J, Colditz GA, Bird AP, Oster G. Lifetime health and economic consequences of obesity. Arch Intern Med 1999;159:2177–2183.

    Google Scholar 

  31. Fuchs FD, Chambless LE, Whelton PK, Nieto FJ, Heiss G. Alcohol consumption and the incidence of hypertension: The atherosclerosis risk in communities study. Hypertension 2001;37:1242–1250.

    Google Scholar 

  32. Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension 1996;27:481–490.

    Google Scholar 

  33. Slowinska-Srzednicka J, Zgliczynski S, Pucilowska J. Studies on the pathogenesis of arterial hypertension in acromegaly: The renin-angiotensin-aldosterone system. Pol Arch Med Wew 1983;69:129–136.

    Google Scholar 

  34. Grisoli F, Leclercq T, Jaquet P, Guibout M, Winteler JP, Hassoun J, Vincentelli F. Transsphenoidal surgery for acromegaly: Long-term results in 100 patients. Surg Neurol 1985;23:513–519.

    Google Scholar 

  35. Minniti G, Moroni C, Jaffrain-Rea ML, Esposito V, Santoro A, Affricano C, Cantore G, Tamburrano G, Cassone R. Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients. Clin Endocrinol (Oxf) 2001;55:307–313.

    Google Scholar 

  36. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001;86:2779–2786.

    Google Scholar 

  37. Thuesen L, Christensen SE, Weeke J, Orskov H. Henningsen P. The cardiovascular effects of octreotide treatment in acromegaly: An echocardiographic study. Clin Endocrinol (Oxf) 1989;30:619–625.

    Google Scholar 

  38. Souadjian JV, Schirger A. Hypertension in acromegaly. Am J Med Sci 1967;254:629–633.

    Google Scholar 

  39. Moller J, Nielsen S, Hansen TK. Growth hormone and fluid retention. Horm Res 1999;51(Suppl 3):116–120.

    Google Scholar 

  40. Ho KY, Kelly JJ. Role of growth hormone in fluid homeostasis. Horm Res 1991;36(Suppl 1):44–48.

    Google Scholar 

  41. Davies DL, Beastall GH, Connel JMC, Fraser R, McCruden D, Teasdale GM. Body composition, blood pressure, and the renin-angiotensin system in acromegaly before and after treatment. J Hypertens 1985;3(Suppl 3):S413–S415.

    Google Scholar 

  42. Feld S, Hirschberg R. Growth hormone, the insulinlike growth factor system, and the kidney. Endocr Rev 1996;17:423–480.

    Google Scholar 

  43. Hansen TK, Moller J, Thomsen K, Frandsen E, Dall R, Jorgensen JO, Christiansen JS. Effects of growth hormone on renal tubular handling of sodium in healthy humans. Am J Physiol Endocrinol Metab 2001;281:E1326–E1332.

    Google Scholar 

  44. Dorup I, Clausen T. Insulin-like growth factor I stimulates active Na(+)-K+transport in rat soleus muscle.AmJ Physiol 1995;268:E849–E857.

    Google Scholar 

  45. Herlitz H, Jonsson O, Bengtsson BA. Relationship between plasma growth hormone concentration and cellular sodium transport in acromegaly. Acta Endocrinol (Copenh) 1992;127:38–43.

    Google Scholar 

  46. Wyse B, Waters M, Sernia C. Stimulation of the reninangiotensin system by growth hormone in Lewis dwarf rats. Am J Physiol 1993;265:E332–E339.

    Google Scholar 

  47. Ho KY, Weissberger AJ. The antinatriuretic action of biosynthetic human growth hormone in man involves activation of the renin-angiotensin system. Metabolism 1990;39:133–137.

    Google Scholar 

  48. Moller J, Frandsen E, Fisker S, Jorgensen JO, Christiansen JS. Decreased plasma and extracellular volume in growth hormone deficient adults and the acute and prolonged effects of GH administration: A controlled experimental study. Clin Endocrinol (Oxf) 1996;44:533–539.

    Google Scholar 

  49. Moller J, Jorgensen JO, Marqversen J, Frandsen E, Christiansen JS. Insulin-like growth factor I administration induces fluid and sodium retention in healthy adults: Possible involvement of renin and atrial natriuretic factor. Clin Endocrinol (Oxf) 2000;52:181–186.

    Google Scholar 

  50. Cain JP, Williams GH, Dluhy RG. Plasma renin activity and aldosterone secrotion in patients with acromegaly. J Clin Endocrinol 1972;34:73–81.

    Google Scholar 

  51. Ogihara T, Hata T, Maruyama A, Mikami H, Nakamaru M, Okada Y, Kumahara Y. Blood pressure response to an angiotensin II antagonist in patients with acromegaly. J Clin Endocrinol Metab 1979;48:159–162.

    Google Scholar 

  52. Strauch G, Vallotton MB, Touitou Y, Bricaire H. The reninangiotensin-aldosterone system in normotensive and hypertensive patients with acromegaly. N Engl J Med 1972;287: 795–799.

    Google Scholar 

  53. Ritchie CM, Sheridan B, Fraser R, Hadden DR, Kennedy AL, Riddel J, Atkinson AB. Studies in the pathogenesis of hypertension in Cushing's disease and acromegaly. Q J Med 1990;280:855–867.

    Google Scholar 

  54. Moore TJ, Thein-Wai W, Dluhy RG, Dawson-Hughes BF, Hollenberg NK, Williams GH. Abnormal adrenal and vascular responses to angiotensin II and an angiotensin antagonist in acromegaly. J Clin Endocrinol Metab 1980;51:215–222.

    Google Scholar 

  55. Mantero F, Opocher G, Armanini D, Paviotti G, Boscaro M, Muggeo M. Plasma renin activity and urinary aldosterone in acromegaly. J Endocrinol Invest 1979;2:13–18.

    Google Scholar 

  56. Karlberg BE, Ottoson AM. Acromegaly and hypertension: Role of the renin-angiotensin-aldosterone system. Acta Endocrinol 1982;100:581–587.

    Google Scholar 

  57. Lin CJ, Mendonca BB, Lucon AM, Guazzelli IC, Nicolau W, Villares SM. Growth hormone receptor messenger ribonucleic acid in normal and pathologic human adrenocortical tissues–An analysis by quantitative polymerase chain reaction technique. J Clin Endocrinol Metab 1997;82:2671–2676.

    Google Scholar 

  58. Rioperez E, Botella JM, Valdivieso L, Ballesteros D, Diez L, Navas J. Conn's syndrome in a patients with acromegaly. Horm Metab Res 1981;13:186–187.

    Google Scholar 

  59. McKnight JA, McCance DR, Hadden DR, Kennedy L, Roberts G, Sheridan B, Atkinson AB. Basal and saline-stimulated levels of plasma atrial natriuretic factor in acromegaly. Clin Endocrinol 1989;31:431–438.

    Google Scholar 

  60. Moller J, Jorgensen JOL, Moller N, Hansen KW, Pedersen EB, Christiansen JS. Expansion of extracellular volume and suppression of atrial natriuretic peptide after growth hormoneadministration in normal man. J Clin Endocrinol Metab 1991;72:768–772.

    Google Scholar 

  61. Donath MY, Gosteli-Peter MA, Hauri C, Froesch ER, Zapf J. Insulin-like growth factor-I stimulates myofibrillar genes and modulates atrial natriuretic factor mRNA in rat heart. Eur J Endocrinol 1997;137:309–315.

    Google Scholar 

  62. Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H, Koga M, Saitoh Y, Ohnishi T, Arita N. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 2000;52:549–555.

    Google Scholar 

  63. Ikeda T, Terasawa H, Ishimura M, Ochi H, Ohtani I, Fujiyama K, Hoshino T, Tanaka Y, Mashiba H. Correlation between blood pressure and plasma insulin in acromegaly. J Int Med 1993;234:61–63.

    Google Scholar 

  64. Slowinska-Srzednicka J, Zgliczynski S, Soszynski P, Zgliczynski W, Jeske W. High blood pressure and hyperinsulinaemia in acromegaly and in obesity. Clin Exp Hypertens 1989;A11:407–425.

    Google Scholar 

  65. Reaven GM, Lithell H, Lansberg L. Hypertension and associated metabolic abnormalities–The role of insulin resistance and the sympathoadrenal system.NEngl J Med1996;334:374–381.

    Google Scholar 

  66. Sowers JR. Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology. Hypertension 1997;29:691–699.

    Google Scholar 

  67. Kirpichnikov D, Sowers JR. Diabetes mellitus and diabetesassociated vascular disease. Trends Endocrinol Metab 2001;12:225–230.

    Google Scholar 

  68. Muller DC, Elahi D, Pratley RE, Tobin JD, Andres R. An epidemiological test of the hyperinsulinemia-hypertension hypothesis. J Clin Endocrinol Metab 1993;76:544–548.

    Google Scholar 

  69. Cryer P. Plasma norepinephrine and epinephrine in acromegaly. J Clin Endocrinol Metab 1975;41:542–545.

    Google Scholar 

  70. Van Loon GR. Abnormal plasma catecholamine response in acromegalics. J Clin Endocrinol Metab 1979;48:784–789.

    Google Scholar 

  71. Bondanelli M, Ambrosio MR, Franceschetti P, Margutti A, Trasforini G, degli Uberti EC. Diurnal rhythm of plasma catecholamines in acromegaly. J Clin Endocrinol Metab 1999;84:2458–2467.

    Google Scholar 

  72. Capaldo B, Lembo G, Rendina V, Guida R, Marzullo P, Colao A, Lombardi G, Sacca L. Muscle sympathetic nerve activity in patients with acromegaly. J Clin Endocrinol Metab 2000;85:3203–3207.

    Google Scholar 

  73. Rozenberg I, Manchon P, Sabatier C, Hazard J, Lhoste F. Effects of thyrotrophin-releasing hormone on plasma catecholamine levels in acromegaly. Acta Endocrinol 1985;109:19–24.

    Google Scholar 

  74. Del Rio G, Velardo A, Mascadri C, Zalteri G, Papi G, Menozzi R, Giustina A. Baseline and stimulated catecholamine secretion in normotensive patients with active acromegaly: Acute effects of continuous octreotide infusion. Eur J Endocrinol 2000;142:179–186.

    Google Scholar 

  75. Hwang O, Choi HJ. Induction of gene expression of the catecholamine-synthetizing enzymes by insulin-like growth factor-I. J Neurochem 1995;65:1988–1996.

    Google Scholar 

  76. Russel-Jones DL, Umpleby AM, Shojaee-Moradie F, Boroujerdi MA, Jones RH, Baxter RC, Sonksen PH. The effect of an intravenous infusion of IGF-I and insulin on IGBP-1, IGFBP-3, acid lable subunit, free and bound IGF-I, catecholamines and potassium in normal volunteers during an amino acid glucose clamp. Clin Endocrinol (Oxf) 1997;47:685–691.

    Google Scholar 

  77. Schini-Kerth VB. Dual effects of insulin-like growth factor-I on the constitutive and inducible nitric oxide (NO) synthasedependent formation of NO in vascular cells. J Endocrinol Invest 1999;22(Suppl 5):82–88.

    Google Scholar 

  78. Terzolo M, Matrella C, Boccuzzi A, Luceri S, Borriero M, Reimondo G, Pia A, Rovero E, Paccotti P, Angeli A. Twenty-four hour profile of blood pressure in patients with acromegaly. Correlation with demographic, clinical and hormonal features. J Endocrinol Invest 1999;22:48–54.

    Google Scholar 

  79. White WB. Ambulatory blood pressure as a predictor of target organ disease and outcome in the hypertensive patient. Blood Press Monit 1999;4:181–184.

    Google Scholar 

  80. Kohara K, Nishida W, Maguchi M, Hiwada K. Autonomic nervous function in non-dipper essential hypertensive subjects. Evaluation by power spectral analysis of heart rate variability. Hypertension 1995;26:808–814.

    Google Scholar 

  81. Chen JW, Jen SL, Lee WL, Hsu NW, Lin SJ, Ting CT, Chang MS, Wang PH. Differential glucose tolerance in dipper and nondipper essential hypertension: The implications of circadian blood pressure regulation on glucose tolerance in hypertension. Diabetes Care 1998;21:1743–1748.

    Google Scholar 

  82. Tanaka T, Natsume T, Shibata H, Nozawa K, Kojima S, Tsuchiya M, Ashida T, Ikeda M. Circadian rhythm of blood pressure in primary aldosteronism and renovascular hypertension–Analysis by the cosinor method. Jpn Circ J 1983;47:788–794.

    Google Scholar 

  83. Ruschitzka F, Schulz E, Kling H, Schrader J, Rath WZ. Longitudinal study of 24-hour blood pressure behavior in pregnancy and puerperium in patients with normal pregnancy, pre-eclampsia and HELLP syndrome. Geburtshilfe Neonatol 1996;200:100–103.

    Google Scholar 

  84. Baumgart P, Walger P, Gemen S, von Eiff M, Raidt H, Rahn KH. Blood pressure elevation during the night in chronic renal failure, hemodialysis and after renal transplantation. Nephron 1991;57:293–298.

    Google Scholar 

  85. Suzuki M, Kimura Y, Tsushima M, Harano Y. Association of insulin resistance with salt sensitivity and nocturnal fall of blood pressure. Hypertension 2000;35:864–868.

    Google Scholar 

  86. Lanfranchi P, Somers VK. Obstructive sleep apnea and vascular disease. Respir Res 2001;2:315–319.

    Google Scholar 

  87. Lavie P, Herer P, Hoffstein V. Obstructive sleep apnoea syndrome as a risk factor for hypertension: Population study. BMJ2000;320:479–482.

    Google Scholar 

  88. Grunstein RR, Ho KY, Sullivan CE. Sleep apnea in acromegaly. Ann Intern Med 1991;115:527–532.

    Google Scholar 

  89. Elmasry A, Lindberg E, Hedner J, Janson C, Boman G. Obstructive sleep apnoea and urine catecholamines in hypertensive males: A population-based study. Eur Respir J 2002;19:511–517.

    Google Scholar 

  90. Bohlooly-YM, Carlson L, Olsson B, Gustafsson H, Andersson IJ, Tornell J, Bergstrom G. Vascular function and blood pressure in GH transgenic mice. Endocrinology 2001;142:3317–3323.

    Google Scholar 

  91. Maison P, Demolis P, Young J, Schaison G, Giudicelli JF, Chanson P. Vascular reactivity in acromegalic patients: Preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction. Clin Endocrinol (Oxf) 2000;53:445–451.

    Google Scholar 

  92. Manelli F, Desenzani P, Boni E, Bugari G, Negrini F, Romanelli G, Grassi V, Giustina A. Cardiovascular effects of a single slow release lanreotide injection in patients with acromegaly and left ventricular hypertrophy. Pituitary 1999;2:205–210.

    Google Scholar 

  93. Thuesen L, Christensen SE, Weeke J, Orskov H, Henningsen P. A hyperkinetic heart in uncomplicated active acromegaly. Explanation of hypertension in acromegalic patients? Acta Med Scand 1988;223:337–343.

    Google Scholar 

  94. King GL, Goodman AD, Buzrey S, Masis A, Kahn CR. Receptors and growth-promoting effects of insulin and insulin-like growth factors on cells from bovine retinal capillaries and aorta. J Clin Invest 1985;75:1028–1036.

    Google Scholar 

  95. Chen Y, Bornfeldt KE, Arner A, Jennische E, Malmqvist U, Uvelius B, Arnqvist HJ. Increase in insulin-like growth factor-I in hypertrophying smooth muscle. Am J Physiol 1994;266:E224–E229.

    Google Scholar 

  96. Kamide K, Hori MT, Zhu JH, Takagawa Y, Barrett JD, Eggena P, Tuck ML. Insulin and insulin-like growth factor-I promotes angiotensinogen production and growth in vascular smooth muscle cells. J Hypertens 2000;18:1051–1056.

    Google Scholar 

  97. Wickman A, Friberg P, Adams MA, Matejka GL, Brantsing C, Guron G, Isgaard J. Induction of growth hormone receptor and insulin-like growth factor-I mRNA in aorta and caval vein during hemodynamic challenge. Hypertension 1997;29:123–130.

    Google Scholar 

  98. Guron G, Friberg P, Wickman A, Brantsing C, Gabrielsson B, Isgaard J. Cardiac insulin-like growth factor I and growth hormone receptor expression in renal hypertension. Hypertension 1996;27:636–642.

    Google Scholar 

  99. Bruel A, Oxlund H. Growth hormone influences the content and composition of collagen in the aorta from old rats. Mech Ageing Dev 2002;123:627–635.

    Google Scholar 

  100. Colao A, Spiezia S, Cerbone G, Pivonello R, Marzullo P, Ferone D, Di Somma C, Assanti AP, Lombardi G. Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. Clin Endocrinol (Oxf) 2001;54:515–524.

    Google Scholar 

  101. Galderisi M, Vitale G, Lupoli G, Barbieri M, Varricchio G, Carella C, de Divitiis O, Paolisso G. Inverse association between free insulin-like growth factor-1 and isovolumic relaxation in arterial systemic hypertension. Hypertension 2001;38:840–845.

    Google Scholar 

  102. Vecchione C, Colella S, Fratta L, Gentile MT, Selvetella G, Frati G, Trimarco B, Lembo G. Impaired insulin-like growth factor I vasorelaxant effects in hypertension. Hypertension 2001;37:1480–1485.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biomedical Sciences and Advanced Therapies, Section of Endocrinology, University of Ferrara, Ferrara, Italy

    Marta Bondanelli, Maria Rosaria Ambrosio & Ettore C. degli Uberti

Authors
  1. Marta Bondanelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Rosaria Ambrosio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ettore C. degli Uberti
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bondanelli, M., Ambrosio, M.R. & degli Uberti, E.C. Pathogenesis and Prevalence of Hypertension in Acromegaly. Pituitary 4, 239–249 (2001). https://doi.org/10.1023/A:1020798430884

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1020798430884

Search

Navigation